IN2015DN02513A - - Google Patents

Download PDF

Info

Publication number
IN2015DN02513A
IN2015DN02513A IN2513DEN2015A IN2015DN02513A IN 2015DN02513 A IN2015DN02513 A IN 2015DN02513A IN 2513DEN2015 A IN2513DEN2015 A IN 2513DEN2015A IN 2015DN02513 A IN2015DN02513 A IN 2015DN02513A
Authority
IN
India
Prior art keywords
preparation
compounds
antibiotics
ertapenem
intermediates
Prior art date
Application number
Other languages
English (en)
Inventor
Hannes Lengauer
Birgit Endl
Wolfgang Felzmann
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of IN2015DN02513A publication Critical patent/IN2015DN02513A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/02—Preparation
    • C07D477/06—Preparation from compounds already containing the ring or condensed ring systems, e.g. by dehydrogenation of the ring, by introduction, elimination or modification of substituents
    • C07D477/08—Modification of a carboxyl group directly attached in position 2, e.g. esterification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
    • C07D477/20—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/02—Preparation
    • C07D477/06—Preparation from compounds already containing the ring or condensed ring systems, e.g. by dehydrogenation of the ring, by introduction, elimination or modification of substituents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
IN2513DEN2015 2012-10-12 2013-10-11 IN2015DN02513A (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12188351 2012-10-12
PCT/EP2013/071252 WO2014057079A1 (en) 2012-10-12 2013-10-11 Preparation of ertapenem intermediates

Publications (1)

Publication Number Publication Date
IN2015DN02513A true IN2015DN02513A (ar) 2015-09-11

Family

ID=47022553

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2513DEN2015 IN2015DN02513A (ar) 2012-10-12 2013-10-11

Country Status (9)

Country Link
US (2) US9546171B2 (ar)
EP (1) EP2906561A1 (ar)
JP (1) JP2015533142A (ar)
KR (1) KR20150065176A (ar)
CN (1) CN104703986A (ar)
AU (1) AU2013328585A1 (ar)
CA (1) CA2887098A1 (ar)
IN (1) IN2015DN02513A (ar)
WO (1) WO2014057079A1 (ar)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2015DN02513A (ar) * 2012-10-12 2015-09-11 Sandoz Ag
CN113880839A (zh) * 2021-11-01 2022-01-04 石药集团中诺药业（石家庄）有限公司 一种厄他培南钠粗品的合成新方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9202298D0 (en) * 1992-02-04 1992-03-18 Ici Plc Antibiotic compounds
AR008255A1 (es) 1996-07-12 1999-12-29 Merck & Co Inc Procedimiento para sintetizar antibioticos de carbapenem
WO1998057973A1 (en) 1997-06-16 1998-12-23 Merck & Co., Inc. Stabilized carbapenem intermediates and synthetic use
US5872250A (en) * 1997-07-30 1999-02-16 Merck & Co., Inc. Process for synthesizing carbapenem antibiotics
AU2002331885B2 (en) 2001-09-26 2007-07-26 Merck & Co., Inc. Crystalline forms of ertapenem sodium
CN100457760C (zh) * 2005-10-20 2009-02-04 上海交通大学 尔他培南钠盐的制备方法
US8293894B2 (en) 2006-11-20 2012-10-23 Orchid Chemicals & Pharmaceuticals Limited Process for the preparation of carbapenem antibiotic
WO2010124531A1 (zh) * 2009-04-30 2010-11-04 石药集团中奇制药技术（石家庄）有限公司 一种厄他培南中间体、含其的组合物及其制备方法
US20110288289A1 (en) * 2010-05-19 2011-11-24 Savior Lifetec Corporation Preparation of Carbapenem Intermediate and Their Use
US8729260B2 (en) * 2010-05-19 2014-05-20 Savior Lifetec Corporation Process for the preparation of carbapenem using cabapenem intermediates and recovery of cabapenem
KR20120007331A (ko) * 2010-07-14 2012-01-20 주식회사 경보제약 카르바페넴계 화합물들의 개선된 제조방법
CN101935321A (zh) * 2010-07-20 2011-01-05 深圳市海滨制药有限公司 1β甲基碳青霉烯类抗生素的合成方法
CN102731502B (zh) 2011-04-13 2016-08-03 石药集团中奇制药技术（石家庄）有限公司 一种碳青霉烯抗生素的制备方法
CN102351861A (zh) * 2011-08-16 2012-02-15 湖南欧亚生物有限公司 一种厄他培南的工业化制备方法
CN102432611B (zh) * 2011-11-09 2013-11-20 上海希迈医药科技有限公司 一种双保护厄他培南结晶体及其制备方法
CN102731508A (zh) * 2012-07-03 2012-10-17 浙江海翔川南药业有限公司 一种晶体形式的厄他培南中间体及其制备方法和应用
IN2015DN02513A (ar) * 2012-10-12 2015-09-11 Sandoz Ag

Also Published As

Publication number Publication date
CN104703986A (zh) 2015-06-10
US20150274732A1 (en) 2015-10-01
AU2013328585A1 (en) 2015-04-09
US20170166570A1 (en) 2017-06-15
EP2906561A1 (en) 2015-08-19
WO2014057079A1 (en) 2014-04-17
JP2015533142A (ja) 2015-11-19
KR20150065176A (ko) 2015-06-12
US9546171B2 (en) 2017-01-17
CA2887098A1 (en) 2014-04-17

Similar Documents

Publication Publication Date Title
HK1207861A1 (en) Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer bub1
IL235944A0 (en) β-lactamase inhibitor compounds, preparations containing them, methods for their preparation and their uses
IL231591A0 (en) Converted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases
ZA201308395B (en) Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as bace1 and/orbace2 inhibitors
AU2012213775A8 (en) 7-azaindole derivatives
AU2012265219A8 (en) Compounds containing hydrido-tricyano-borate anions
PL2922893T3 (pl) Kompozycje utwardzane wilgocią, sposób ich wytwarzania i ich zastosowania
EP2729464B8 (en) Cyclopropyl-fused-1,3-thiazepines as bace 1 and/or bace 2 inhibitors
IN2014CN04050A (ar)
CA2875305C (en) Fbxo3 inhibitors
HK1199024A1 (zh) 可作為 抑制物使用之新型嗎啉基衍生物
EP3082823A4 (en) Iminothiadiazepane dioxide compounds as bace inhibitors, compositions, and their use
WO2013155338A3 (en) Substituted benzamides and their uses
PH12015500061A1 (en) Method for preparing substituted triazolopyridines
GB201107985D0 (en) Process
UA117567C2 (uk) Композиція, яка стимулює лактацію, на основі фосфатидилсерину
AU2013347232A8 (en) 3-Aminocyclopentane carboxamide derivatives
HK1207079A1 (en) An improved process for the preparation of carbapenem antibiotic
IN2015DN02513A (ar)
UA72478U (ru) Применение полентара как средства фригопротекторного действия
UA80618U (en) Use of n-steroylethanolamine as radiomodifier
MY168958A (en) Intermediates and processes for preparing compounds
EP2903586B8 (en) Composition
IN2013CH00453A (ar)
AU2012903414A0 (en) Composition